Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Non-Current Assets (2022 - 2026)

Sagimet Biosciences' Non-Current Assets history spans 5 years, with the latest figure at $39000.0 for Q1 2026.

  • Quarterly Non-Current Assets fell 61.0% to $39000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Mar 2026, down 59.42% year-over-year, with the annual reading at $78000.0 for FY2025, 98.96% down from the prior year.
  • Non-Current Assets came in at $39000.0 for Q1 2026, down from $78000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $22.3 million in Q2 2024 to a low of $37000.0 in Q1 2024.
  • The 5-year median for Non-Current Assets is $144000.0 (2023), against an average of $5.2 million.
  • Year-over-year, Non-Current Assets soared 16033.03% in 2024 and then plummeted 98.96% in 2025.
  • Sagimet Biosciences' Non-Current Assets stood at $239000.0 in 2022, then crashed by 69.46% to $73000.0 in 2023, then soared by 10153.42% to $7.5 million in 2024, then tumbled by 98.96% to $78000.0 in 2025, then plummeted by 50.0% to $39000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Non-Current Assets are $39000.0 (Q1 2026), $78000.0 (Q4 2025), and $8.9 million (Q3 2025).